In this micro learning programme, you'll learn about PARP inhibitors in prostate cancer from medical experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno. 

Learning resources include videos, slides, flashcards and assessments. Complete both modules to earn your CME credit.

What you'll learn

 

 

Clinical takeaways:

  • PARP inhibitors are effective drugs as monotherapy in mCRPC patients with HRR alterations
  • Genetic testing is important to help with treatment decision-making and for understanding inherited risk
  • BRCA mutations are associated with poor outcomes in mCRPC patients
  • Patients with tumours harbouring BRCA1/BRCA2 alterations appear to derive the greatest clinical benefit from PARPi, but patients with other HRR alterations also derive benefit
  • PARP inhibitors combined with novel hormonal agents are effective as a first-line treatment option for mCRPC patients with an HRR mutation. Certain combinations, such as olaparib plus abiraterone and talazoparib plus enzalutamide, have also shown benefits in patients regardless of their HRR status

Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.

Assoc. Prof. Alicia Morgans has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Myovant, Novartis, Pfizer, Sanofi and Telix. 

Dr Pasquale Rescigno is Clinical Senior Lecturer at the Translational and Clinical Research Institute at Newcastle University, UK. He is the former Head of the Translational and Clinical Trial Team on GU Cancers at the Istituto di Candiolo FPO-IRCCS (Candiolo Cancer Institute), Clinical Research Fellow at the Institute of Cancer Research (London), and Prostate Cancer Foundation Young Investigator awardee.  

His research mainly focuses on the study of mechanisms/pathways that are disrupted in prostate cancer (such as PTEN/PI3K/AKT, TP53 and RB1), and on the identification and validation of predictive, prognostic and efficacy-response biomarkers for novel agents targeting the PI3K/AKT, DNA repair systems and the PD-1/PDL-1 pathways.

He has served as Principal and Sub-investigator of several phase I/II/III Clinical Trials and designed and is the Clinical Coordinator and Principal Investigator of UK and Italian national research projects (MAESTRO, an umbrella trial and PERSEUS1 in the UK; BITCOIN and BRIDGE in Italy).

More recently, his research activity focused on the study of gut microbiome in prostate cancer.
Programme summary
Other modules in this series
PARP inhibitors in prostate cancer and the rationale behind combination treatment

PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

PARP inhibitors in prostate cancer and the rationale behind combination treatment

PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Current Module
Share this programme
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for 0.5 ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
China Europe Anti-Cancer Summit_C2E2403 Other
Oncology 
2nd China-Europe Anti-Cancer Summit 2024: On-demand webinar

Oncologists review basic research and share the latest achievements in clinical practice

Experts
Prof. Yihai Cao, Prof. Ying Wang, Prof. Daiming Fan, Prof. Csaba L. Dégi
  • clock 101 MIN
  • calendar May 2024

This educational programme is supported by an Independent Medical Education Grant from BeiGene.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.